» Articles » PMID: 21889433

Racial Differences in the Presentation and Outcomes of Chronic Lymphocytic Leukemia and Variants in the United States

Overview
Publisher Elsevier
Specialty Oncology
Date 2011 Sep 6
PMID 21889433
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the United States, and prolymphocytic leukemia (PLL) is a related, rare chronic lymphoproliferative disorder.

Methods: Using the United States Surveillance, Epidemiology and End Results (SEER) data from 13 registries, we examined differences in incidence and survival for CLL, small lymphocytic lymphoma (SLL) and PLL by race. International Classification of Diseases for Oncology 3(rd) edition histology codes 9670, 9823, and 9632-34 were used to identify cases.

Results: From 1992 to 2007, 30,622 cases of CLL/SLL and 268 cases of PLL were recorded. Males had higher incidence than females (male-to-female incidence rate ratio CLL/SLL 1.89, 95% confidence interval (CI) 1.85-1.94 and PLL 2.47, 95%CI 1.90-3.20). Black patients were diagnosed at younger age compared to white patients (mean age at diagnosis for white versus black patients for CLL/SLL, 70 versus 67 years, P < .001; for PLL, 71 versus 61 years, P < .001). Greater proportion of black patients with SLL presented with B symptoms, extranodal primary site, and advanced disease compared to white patients (P = .003, P = .012, and P = .009 respectively). White patients with CLL/SLL had better survival rates than black patients (5-year relative survival rate 77.1% versus 63.9%, P < .01). In univariate Cox regression models, black race, male gender, age at diagnosis > 65 years, advanced stage, and B-symptoms were predictors of worse survival (P < .01) among CLL/SLL patients.

Conclusions: Black patients with CLL/SLL and PLL present at younger age and black patients with CLL/SLL have worse survival than white patients. Epidemiological studies examining the biological variants of these diseases in concert with race are needed to elucidate the etiology of these disparities.

Citing Articles

Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry.

de Campos C, McCabe C, Bruins L, OBrien D, Brown S, Tschumper R Blood Cancer J. 2025; 15(1):14.

PMID: 39910036 PMC: 11799526. DOI: 10.1038/s41408-024-01207-3.


Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.

Flowers C, Anantha R, Leautaud V, Desai P, Donald C, Hildebrandt M Blood Cancer Discov. 2025; 6(2):79-93.

PMID: 39898759 PMC: 11876954. DOI: 10.1158/2643-3230.BCD-24-0153.


Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.

Barrientos J, Ayed A, Cha A, Du S, Fang B, Hall R Target Oncol. 2023; 18(5):727-734.

PMID: 37728835 PMC: 10517886. DOI: 10.1007/s11523-023-00988-0.


Health disparity in use of novel agents for first-line therapy in Black and White patients with chronic lymphocytic leukemia in the Department of Veterans Affairs.

Lucero K, Obodozie-Ofoegbu O, Nooruddin Z, Ryan K, Castillo A, Moore A J Manag Care Spec Pharm. 2023; 29(4):420-430.

PMID: 36989449 PMC: 10387978. DOI: 10.18553/jmcp.2023.29.4.420.


Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019.

Kittai A, Huang Y, Bhat S, Paskett E, Rogers K, Barrientos J Blood Adv. 2022; 7(11):2575-2579.

PMID: 36083137 PMC: 10250911. DOI: 10.1182/bloodadvances.2022008643.